{
    "Trade/Device Name(s)": [
        "HemosIL D-Dimer HS 500",
        "HemosIL D-Dimer HS 500 Controls"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K090264",
    "Predicate Device Reference 510(k) Number(s)": [
        "K040882",
        "K070927",
        "K972696"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP",
        "GGN"
    ],
    "Summary Letter Date": "August 12, 2009",
    "Summary Letter Received Date": "August 13, 2009",
    "Submission Date": "August 12, 2009",
    "Regulation Number(s)": [
        "21 CFR 864.7320",
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Fibrinogen and Fibrin Split Products, Antigen, Antiserum, Control (Assay)",
        "Plasma, Coagulation Controls (Controls)"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "D-Dimer"
    ],
    "Specimen Type(s)": [
        "Citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACL TOP Family Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Latex-enhanced immunoturbidimetric assay"
    ],
    "Methodologies": [
        "Immunoturbidimetry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL D-Dimer HS 500 automated latex enhanced immunoassay and associated controls for quantitative determination of D-Dimer in human citrated plasma.",
    "Indications for Use Summary": "Quantitative determination of D-Dimer in human citrated plasma on ACL TOP Family Systems to exclude venous thromboembolism in outpatients suspected of DVT and PE, used with a clinical pretest probability assessment model; controls for quality control of the assay.",
    "fda_folder": "Hematology"
}